BIIB34:BVMF
Biogen Inc BDR
R$244.50
arrow_downward
-0.12%(-0.30) 1H
19 Nov, 4:56:00 PTG GMT-3 · BRL
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk BIIB34...
Buka
R$244.50
Tinggi
R$244.50
Rendah
R$244.50
Permodalan Pasaran
36.53B
Purata volum
9.00
Volum
2.00
tgi 52 mgu
R$244.50
rdh 52 mgu
R$147.50
Syer tertunggak
147.82J
Bilangan pekerja
8K
Buka
R$244.50
Tinggi
R$244.50
Rendah
R$244.50
Permodalan Pasaran
36.53B
Purata volum
9.00
Volum
2.00
tgi 52 mgu
R$244.50
rdh 52 mgu
R$147.50
Syer tertunggak
147.82J
Bilangan pekerja
8K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Investing.com
·
8 jam lalu
H.C. Wainwright reiterates Buy rating on Biogen stock at $270
Trefis
·
12 jam lalu
Should Biogen Stock Holders Look At Amgen Instead?
Yahoo Finance
·
1 hari lalu
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
Investing.com
·
1 hari lalu
Needham reiterates Biogen stock rating on Alzheimer’s drug data
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Perihal Biogen Inc BDR
CEOChris Viehbacher
Pekerja7.5K
Diasaskan1978
Ibu pejabatCambridge, Massachusetts, Amerika Syarikat
SektorHealth Care
Industri-
Laman webbiogen.com